In which patients will you consider the use of adjuvant pertuzumab for HER2 positive early stage breast cancer?
How does the modest results of the APHINITY trial impact your practice?
Answer from: Medical Oncologist at Academic Institution
The benefit of adding pertuzumab to a trastuzumab-based regimen is quite small (0.9% at 3 years, 1.8% in those with involved LNs). This will not change my practice for most patients. Certainly for a patient with multiple involved nodes and ER- disease, the addition of pertuzumab will become a long d...
Sign in or Register to read more